Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?

被引：2
作者：
Othman, Jad [1 ,2 ,3 ]
Dillon, Richard [1 ,4 ]
机构：
[1] Kings Coll London, Dept Med & Mol Genet, London SE1 9RT, England
[2] Royal North Shore Hosp, Dept Haematol, Sydney, Australia
[3] Univ Sydney, Fac Med & Heath, Sydney, Australia
[4] Guys & St Thomas Hosp NHS Trust, Dept Haematol, London, England
来源：
LANCET HAEMATOLOGY | 2023年 / 10卷 / 07期
关键词：
INDUCTION CHEMOTHERAPY; ADULT PATIENTS; SURVIVAL;
D O I：
10.1016/S2352-3026(23)00092-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E478 / E479
页数：2
相关论文
共 10 条
  • [1] Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
    Burnett, Alan K.
    Russell, Nigel H.
    Hills, Robert K.
    Kell, Jonathan
    Freeman, Sylvie
    Kjeldsen, Lars
    Hunter, Ann E.
    Yin, John
    Craddock, Charles F.
    Dufva, Inge Hoegh
    Wheatley, Keith
    Milligan, Donald
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (32) : 3924 - 3931
  • [2] Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
    Burnett, Alan K.
    Hills, Robert K.
    Milligan, Donald
    Kjeldsen, Lars
    Kell, Jonathan
    Russell, Nigel H.
    Yin, John A. L.
    Hunter, Ann
    Goldstone, Anthony H.
    Wheatley, Keith
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) : 369 - 377
  • [3] Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
    Castaigne, Sylvie
    Pautas, Cecile
    Terre, Christine
    Raffoux, Emmanuel
    Bordessoule, Dominique
    Bastie, Jean-Noel
    Legrand, Ollivier
    Thomas, Xavier
    Turlure, Pascal
    Reman, Oumedaly
    de Revel, Thierry
    Gastaud, Lauris
    de Gunzburg, Noemie
    Contentin, Nathalie
    Henry, Estelle
    Marolleau, Jean-Pierre
    Aljijakli, Ahmad
    Rousselot, Philippe
    Fenaux, Pierre
    Preudhomme, Claude
    Chevret, Sylvie
    Dombret, Herve
    [J]. LANCET, 2012, 379 (9825) : 1508 - 1516
  • [4] Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial
    Doehner, Hartmut
    Weber, Daniela
    Krzykalla, Julia
    Fiedler, Walter
    Kuehn, Michael W. M.
    Schroeder, Thomas
    Mayer, Karin
    Luebbert, Michael
    Wattad, Mohammed
    Goetze, Katharina
    Fransecky, Lars
    Koller, Elisabeth
    Wulf, Gerald
    Schleicher, Jan
    Ringhoffer, Mark
    Greil, Richard
    Hertenstein, Bernd
    Krauter, Juergen
    Martens, Uwe M.
    Nachbaur, David
    Abu Samra, Maisun
    Machherndl-Spandl, Sigrid
    Basara, Nadezda
    Leis, Claudia
    Schrade, Anika
    Kapp-Schwoerer, Silke
    Cocciardi, Sibylle
    Bullinger, Lars
    Thol, Felicitas
    Heuser, Michael
    Paschka, Peter
    Gaidzik, Verena I.
    Saadati, Maral
    Benner, Axel
    Schlenk, Richard F.
    Doehner, Konstanze
    Ganser, Arnold
    [J]. LANCET HAEMATOLOGY, 2023, 10 (07): : e495 - e509
  • [5] Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia
    Fournier, Elise
    Duployez, Nicolas
    Ducourneau, Benoit
    Raffoux, Emmanuel
    Turlure, Pascal
    Caillot, Denis
    Thomas, Xavier
    Marceau-Renaut, Alice
    Chantepie, Sylvain
    Malfuson, Jean-Valere
    Lemasle, Emilie
    Cheok, Meyling
    Celli-Lebras, Karine
    Guerin, Estelle
    Terre, Christine
    Lambert, Juliette
    Pautas, Cecile
    Dombret, Herve
    Castaigne, Sylvie
    Preudhomme, Claude
    Boissel, Nicolas
    [J]. BLOOD, 2020, 135 (08) : 542 - 546
  • [6] Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
    Hills, Robert K.
    Castaigne, Sylvie
    Appelbaum, Frederick R.
    Delaunay, Jacques
    Petersdorf, Stephen
    Othus, Megan
    Estey, Elihu H.
    Dombret, Herve
    Chevret, Sylvie
    Ifrah, Norbert
    Cahn, Jean-Yves
    Recher, Christian
    Chilton, Lucy
    Moorman, Anthony V.
    Burnett, Alan K.
    [J]. LANCET ONCOLOGY, 2014, 15 (09) : 986 - 996
  • [7] A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
    Petersdorf, Stephen H.
    Kopecky, Kenneth J.
    Slovak, Marilyn
    Willman, Cheryl
    Nevill, Thomas
    Brandwein, Joseph
    Larson, Richard A.
    Erba, Harry P.
    Stiff, Patrick J.
    Stuart, Robert K.
    Walter, Roland B.
    Tallman, Martin S.
    Stenke, Leif
    Appelbaum, Frederick R.
    [J]. BLOOD, 2013, 121 (24) : 4854 - 4860
  • [8] Russell N., 2022, Hemasphere, V6, P27
  • [9] Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
    Stone, R. M.
    Mandrekar, S. J.
    Sanford, B. L.
    Laumann, K.
    Geyer, S.
    Bloomfield, C. D.
    Thiede, C.
    Prior, T. W.
    Doehner, K.
    Marcucci, G.
    Lo-Coco, F.
    Klisovic, R. B.
    Wei, A.
    Sierra, J.
    Sanz, M. A.
    Brandwein, J. M.
    de Witte, T.
    Niederwieser, D.
    Appelbaum, F. R.
    Medeiros, B. C.
    Tallman, M. S.
    Krauter, J.
    Schlenk, R. F.
    Ganser, A.
    Serve, H.
    Ehninger, G.
    Amadori, S.
    Larson, R. A.
    Doehner, H.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (05) : 454 - 464
  • [10] Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group
    Tarlock, Katherine
    Alonzo, Todd A.
    Gerbing, Robert B.
    Raimondi, Susana C.
    Hirsch, Betsy A.
    Sung, Lillian
    Pollard, Jessica A.
    Aplenc, Richard
    Loken, Michael R.
    Gamis, Alan S.
    Meshinchi, Soheil
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (08) : 1951 - 1957
1